Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer

被引:26
作者
Cui, Nai-Peng [1 ,2 ]
Qiao, Shu [1 ]
Jiang, Shan [1 ]
Hu, Jin-Lin [1 ]
Wang, Ting-Ting [1 ]
Liu, Wen-Wen [2 ,3 ]
Qin, Yan [2 ,3 ]
Wang, Ya-Nan [4 ]
Zheng, Li-Shuang [3 ]
Zhang, Jin-Chao [5 ,6 ]
Ma, Yong-Ping [7 ]
Chen, Bao-Ping [1 ]
Shi, Jian-Hong [2 ,3 ]
机构
[1] Hebei Univ, Dept Breast Surg, Hebei Key Lab Canc Radiotherapy & Chemotherapy, Affiliated Hosp, Baoding, Peoples R China
[2] Hebei Univ, Inst Life Sci & Green Dev, Baoding, Peoples R China
[3] Hebei Univ, Cent Lab, Hebei Key Lab Canc Radiotherapy & Chemotherapy, Affiliated Hosp, Baoding, Peoples R China
[4] Hebei Univ, Dept Pathol, Affiliated Hosp, Baoding, Peoples R China
[5] Hebei Univ, Coll Chem & Environm Sci, Key Lab Analyt Sci & Technol Hebei Prov, Baoding, Peoples R China
[6] Hebei Univ, MOE Key Lab Med Chem & Mol Diagnost, Baoding, Peoples R China
[7] Baoding Second Hosp, Dept Stomatol, Baoding, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
PTK7; triple-negative breast cancer (TNBC); migration; progression; EGFR; PTK7; EXPRESSION; CELL POLARITY; TARGET;
D O I
10.3389/fonc.2021.699889
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is associated with high invasiveness, high metastatic occurrence and poor prognosis. Protein tyrosine kinase 7 (PTK7) plays an important role in multiple cancers. However, the role of PTK7 in TNBC has not been well addressed. This study was performed to evaluate the role of PTK7 in the progression of TNBC. & nbsp; Methods Correlation of PTK7 expression with clinicopathological parameters was assessed using tissue microarray immunohistochemistry (IHC) staining in 280 patients with breast cancer. PTK7 expression in TNBC (MDA-MB-468, MDA-MB-436 and MDA-MB-231) and non-TNBC (MCF7 and SK-BR-3) breast cancer cell lines were examined using immunoblotting assay. PTK7 correlated genes in invasive breast carcinoma were analyzed using cBioPortal breast cancer datasets including 1,904 patients. PTK7 overexpressed or knockdown TNBC cell lines (MDA-MB-468 and MDA-MB-436) were used to analyze the potential roles of PTK7 in TNBC metastasis and tumor progression. A TNBC tumor bearing mouse model was established to further analyze the role of PTK7 in TNBC tumorigenicity in vivo. & nbsp; Results PTK7 is highly expressed in breast cancer and correlates with worse prognosis and associates with tumor metastasis and progression in TNBC. Co-expression analysis and gain- or loss-of-function of PTK7 in TNBC cell lines revealed that PTK7 participates in EGFR/Akt signaling regulation and associated with extracellular matrix organization and migration genes in breast cancer, including COL1A1, FN1, WNT5B, MMP11, MMP14 and SDC1. Gain- or loss-of-function experiments of PTK7 suggested that PTK7 promotes proliferation and migration in TNBC cell lines. PTK7 knockdown MDA-MB-468 cell bearing mouse model further demonstrated that PTK7-deficiency inhibits TNBC tumor progression in vivo. & nbsp; Conclusion This study identified PTK7 as a potential marker of worse prognosis in TNBC and revealed PTK7 promotes TNBC metastasis and progression via EGFR/Akt signaling pathway.
引用
收藏
页数:13
相关论文
共 36 条
  • [1] Ataseven B, 2013, ANTICANCER RES, V33, P3759
  • [2] Drug Repurposing for Triple-Negative Breast Cancer
    Avalos-Moreno, Marta
    Lopez-Tejada, Araceli
    Blaya-Canovas, Jose L.
    Cara-Lupianez, Francisca E.
    Gonzalez-Gonzalez, Adrian
    Lorente, Jose A.
    Sanchez-Rovira, Pedro
    Granados-Principal, Sergio
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 34
  • [3] Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020
    Azim, Hamdy A.
    Ghosn, Marwan
    Oualla, Karima
    Kassem, Loay
    [J]. BREAST JOURNAL, 2020, 26 (01) : 69 - 80
  • [4] Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC
    Bao, Xuanwen
    Shi, Run
    Zhao, Tianyu
    Wang, Yanfang
    Anastasov, Natasa
    Rosemann, Michael
    Fang, Weijia
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (01) : 189 - 202
  • [5] PTK7 promotes the malignant properties of cancer stem-like cells in esophageal squamous cell lines
    Bie, Jun
    Hu, Xin
    Yang, Mi
    Shi, Xianwei
    Zhang, Xinping
    Wang, Ziwei
    [J]. HUMAN CELL, 2020, 33 (02) : 356 - 365
  • [6] Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
    Butti, Ramesh
    Das, Sumit
    Gunasekaran, Vinoth Prasanna
    Yadav, Amit Singh
    Kumar, Dhiraj
    Kundu, Gopal C.
    [J]. MOLECULAR CANCER, 2018, 17
  • [7] Prognostic significance of PTK7 in human malignancies
    Chen, Gang
    Qi, Shengcai
    Yang, Xi
    Chen, Wantao
    [J]. HISTOLOGY AND HISTOPATHOLOGY, 2018, 33 (04) : 379 - 388
  • [8] A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
    Damelin, Marc
    Bankovich, Alexander
    Bernstein, Jeffrey
    Lucas, Justin
    Chen, Liang
    Williams, Samuel
    Park, Albert
    Aguilar, Jorge
    Ernstoff, Elana
    Charati, Manoj
    Dushin, Russell
    Aujay, Monette
    Lee, Christina
    Ramoth, Hanna
    Milton, Milly
    Hampl, Johannes
    Lazetic, Sasha
    Pulito, Virginia
    Rosfjord, Edward
    Sun, Yongliang
    King, Lindsay
    Barletta, Frank
    Betts, Alison
    Guffroy, Magali
    Falahatpisheh, Hadi
    O'Donnell, Christopher J.
    Stull, Robert
    Pysz, Marybeth
    Escarpe, Paul
    Liu, David
    Foord, Orit
    Gerber, Hans Peter
    Sapra, Puja
    Dylla, Scott J.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (372)
  • [9] Crosstalk between receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCR) in the brain: Focus on heteroreceptor complexes and related functional neurotrophic effects
    Di Liberto, Valentina
    Mudo, Giuseppa
    Belluardo, Natale
    [J]. NEUROPHARMACOLOGY, 2019, 152 : 67 - 77
  • [10] Duan F, 2020, EUR REV MED PHARMACO, V24, P6809, DOI 10.26355/eurrev_202006_21670